PARP1 and cancer: Our group has demonstrated that combining low-dose DNMTi treatment with the potent PARP-trapping PARPi talazoparib enhances PARP1-DNA binding, synergistically enhancing cytotoxicity across a number of BRCA-wildtype cancer types with minimal toxicity in in vivo models [32,33,34] or human subjects [35,36].